Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O E Tsitsilonis

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Vitamins and Hormones|July 25, 2016
Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?P Samara, K Ioannou, O E Tsitsilonis
Electrophoresis|May 1, 1997
Prothymosin alpha: efficient sequence determination by experimental and theoretical capillary electrophoretic supportA Weiler, S Stoeva, O E Tsitsilonis, et al.
Journal of Chemotherapy (Florence, Italy)|September 10, 2003
Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot studyO E Tsitsilonis, N B Tsavaris, C Kosmas, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1995
Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alphaC N Baxevanis, A D Gritzapis, G Spanakos, et al.
Journal of Evolutionary Biology|May 22, 2016
Infection risk dictates immunological divergence among populations in a Mediterranean lizardK Sagonas, I A Rota, O E Tsitsilonis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2000
Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumorC N Baxevanis, I F Voutsas, O E Tsitsilonis, et al.
European Journal of Immunology|August 15, 2000
Compromised anti-tumor responses in tumor necrosis factor-alpha knockout miceC N Baxevanis, I F Voutsas, O E Tsitsilonis, et al.
Blood Cancer Journal|August 26, 2017
Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosisI V Kostopoulos, G Paterakis, D Pavlidis, et al.
Cancer Immunology, Immunotherapy : CII|July 22, 1999
Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alphaC N Baxevanis, G Spanakos, I F Voutsas, et al.
Immunopharmacology and Immunotoxicology|September 15, 1998
Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicityC N Baxevanis, I F Voutsas, M H Soler, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Vitamins and Hormones|July 25, 2016
Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?P Samara, K Ioannou, O E Tsitsilonis
Electrophoresis|May 1, 1997
Prothymosin alpha: efficient sequence determination by experimental and theoretical capillary electrophoretic supportA Weiler, S Stoeva, O E Tsitsilonis, et al.
Journal of Chemotherapy (Florence, Italy)|September 10, 2003
Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot studyO E Tsitsilonis, N B Tsavaris, C Kosmas, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1995
Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alphaC N Baxevanis, A D Gritzapis, G Spanakos, et al.
Journal of Evolutionary Biology|May 22, 2016
Infection risk dictates immunological divergence among populations in a Mediterranean lizardK Sagonas, I A Rota, O E Tsitsilonis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2000
Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumorC N Baxevanis, I F Voutsas, O E Tsitsilonis, et al.
European Journal of Immunology|August 15, 2000
Compromised anti-tumor responses in tumor necrosis factor-alpha knockout miceC N Baxevanis, I F Voutsas, O E Tsitsilonis, et al.
Blood Cancer Journal|August 26, 2017
Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosisI V Kostopoulos, G Paterakis, D Pavlidis, et al.
Cancer Immunology, Immunotherapy : CII|July 22, 1999
Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alphaC N Baxevanis, G Spanakos, I F Voutsas, et al.
Immunopharmacology and Immunotoxicology|September 15, 1998
Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicityC N Baxevanis, I F Voutsas, M H Soler, et al.
Pageof 2